Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NASDAQ:BOLD NASDAQ:IOBT NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$2.03-1.0%$2.08$1.33▼$3.16$96.62M0.7586,206 shs24,231 shsBOLDBoundless Bio$1.15-50.2%$59.97$1.00▼$4.72$25.30M-1.2260,666 shs96,520 shsIOBTIO Biotech$1.58-1.3%$1.82$0.66▼$2.79N/A0.411.13 million shs1.28 million shsTCRXTScan Therapeutics$1.84+2.2%$1.79$1.02▼$6.23$102.15M1219,443 shs286,847 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene+1.99%-3.76%-14.23%+5.67%-8.89%BOLDBoundless Bio+1.95%+0.44%-1.71%+8.49%-68.92%IOBTIO Biotech+7.38%-6.98%-8.05%+5.96%+42.86%TCRXTScan Therapeutics+1.12%+4.65%-3.74%+16.88%-65.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$2.03-1.0%$2.08$1.33▼$3.16$96.62M0.7586,206 shs24,231 shsBOLDBoundless Bio$1.15-50.2%$59.97$1.00▼$4.72$25.30M-1.2260,666 shs96,520 shsIOBTIO Biotech$1.58-1.3%$1.82$0.66▼$2.79N/A0.411.13 million shs1.28 million shsTCRXTScan Therapeutics$1.84+2.2%$1.79$1.02▼$6.23$102.15M1219,443 shs286,847 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene+1.99%-3.76%-14.23%+5.67%-8.89%BOLDBoundless Bio+1.95%+0.44%-1.71%+8.49%-68.92%IOBTIO Biotech+7.38%-6.98%-8.05%+5.96%+42.86%TCRXTScan Therapeutics+1.12%+4.65%-3.74%+16.88%-65.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 3.00Buy$7.00244.83% UpsideBOLDBoundless Bio 2.25Hold$3.50205.68% UpsideIOBTIO Biotech 3.33Buy$8.00406.33% UpsideTCRXTScan Therapeutics 3.00Buy$7.80323.91% UpsideCurrent Analyst Ratings BreakdownLatest BOLD, TCRX, IOBT, and ADAG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025ADAGAdageneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.008/12/2025IOBTIO BiotechMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$6.00 ➝ $4.008/12/2025TCRXTScan TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.008/11/2025BOLDBoundless BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.008/6/2025ADAGAdageneLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025ADAGAdageneLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$100K956.74N/AN/A$1.14 per share1.78BOLDBoundless BioN/AN/AN/AN/A$6.76 per shareN/AIOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/ATCRXTScan Therapeutics$2.82M37.03N/AN/A$4.26 per share0.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$33.42MN/A0.00N/AN/AN/AN/AN/AN/ABOLDBoundless Bio-$65.36MN/A0.00N/AN/AN/A-44.79%-34.24%N/AIOBTIO Biotech-$95.49M-$1.580.00N/AN/AN/A-281.82%-169.29%11/11/2025 (Estimated)TCRXTScan Therapeutics-$127.50M-$1.090.00N/AN/A-1,964.88%-63.33%-40.19%11/11/2025 (Estimated)Latest BOLD, TCRX, IOBT, and ADAG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IOBTIO Biotech-$0.35-$0.40-$0.05-$0.40N/AN/A8/12/2025Q2 2025TCRXTScan Therapeutics-$0.28-$0.2848-$0.0048-$0.28$1.31 million$3.08 million8/5/2025Q2 2025BOLDBoundless Bio-$0.75-$0.70+$0.05-$0.70N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/ABOLDBoundless BioN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.012.292.30BOLDBoundless Bio0.3914.0814.08IOBTIO Biotech4.221.961.96TCRXTScan Therapeutics0.187.067.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%BOLDBoundless BioN/AIOBTIO Biotech54.76%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%BOLDBoundless Bio21.10%IOBTIO Biotech4.80%TCRXTScan Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.13 million37.14 millionNot OptionableBOLDBoundless Bio20722.39 million17.66 millionNo DataIOBTIO Biotech30N/AN/ANot OptionableTCRXTScan Therapeutics10056.75 million54.28 millionNot OptionableBOLD, TCRX, IOBT, and ADAG HeadlinesRecent News About These CompaniesTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of "Buy" from AnalystsSeptember 22 at 3:15 AM | marketbeat.comTScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025September 17, 2025 | globenewswire.comEcoR1 Capital LLC Sells 4,337,167 Shares of TScan Therapeutics, Inc. $TCRXSeptember 6, 2025 | marketbeat.comTScan Therapeutics, Inc. $TCRX Shares Bought by Checkpoint Capital L.P.September 6, 2025 | marketbeat.comBVF Inc. IL Purchases 1,900,000 Shares of TScan Therapeutics, Inc. $TCRXSeptember 5, 2025 | marketbeat.comTScan Therapeutics to Participate in Upcoming Investor ConferencesSeptember 3, 2025 | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by BrokeragesAugust 30, 2025 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash WiselyAugust 15, 2025 | finance.yahoo.comTScan Therapeutics Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comTScan Therapeutics reports Q2 EPS (28c), consensus (32c)August 12, 2025 | msn.comTScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue EstimatesAugust 12, 2025 | zacks.comTScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comTScan Therapeutics Elects New Directors at Annual MeetingJuly 27, 2025 | theglobeandmail.comOne TScan Therapeutics Insider Raised Stake By 18% In Previous YearJuly 19, 2025 | finance.yahoo.comTscan Therapeutics Inc News (TCRX) - Investing.comJuly 9, 2025 | investing.comTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comLynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockMay 22, 2025 | insidertrades.comWhat Analysts Are Saying About TScan Therapeutics StockMay 9, 2025 | nasdaq.com3TCRX : What Analysts Are Saying About TScan Therapeutics StockMay 7, 2025 | benzinga.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comTScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBOLD, TCRX, IOBT, and ADAG Company DescriptionsAdagene NASDAQ:ADAG$2.03 -0.02 (-0.98%) Closing price 03:55 PM EasternExtended Trading$2.10 +0.07 (+3.20%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Boundless Bio NASDAQ:BOLDAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.IO Biotech NASDAQ:IOBT$1.58 -0.02 (-1.25%) Closing price 04:00 PM EasternExtended Trading$1.60 +0.02 (+1.58%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.TScan Therapeutics NASDAQ:TCRX$1.84 +0.04 (+2.22%) Closing price 04:00 PM EasternExtended Trading$1.86 +0.01 (+0.82%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm’s RSI Just Hit Its High of the Year—Why That’s Bullish 2 Ways to Trade Amazon Ahead of October’s Prime Day AutoZone Pulls Into a Buy-the-Dip Opportunity Rocket Lab’s Bullish Case Remains Intact Despite Recent Offering Broadcom Price Targets Just Reached Above $400 for the First Time Replace Your Fixed Income With This Dividend ETF These 3 Mega-Cap Giants Just Increased Dividends by 7% or More Ford Set to Outpace GM With Tariff Tailwinds and EPS Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
